At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 22, 2026 at 16:03 ET
Keros Therapeutics is holding its 2026 annual shareholder meeting virtually on June 3, 2026. The board recommends voting for the election of Jean-Jacques Bienaimé and Charles Newton as Class III directors, ratifying Deloitte & Touche LLP as auditors, and approving executive compensation.
- Annual meeting date: June 3, 2026
- Meeting will be held virtually
- Board recommends voting FOR all proposals
- Proposal 1: Elect Jean-Jacques Bienaimé and Charles Newton as Class III directors
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access